// Company Overview //
| Stock Name | 复锐医疗科技 |
| Stock Code | 01696 |
| Company Full Name | 复锐医疗科技 |
| Industry | 醫療保健 |
| Principal Activities | 主要從事設計、開發、制造及銷售醫療美容器械。 |
| Listing Date | 2017-09-19 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 3079895 以色列凱撒利亞工業園區哈哈拉什街18號Ofek 15號樓 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | http://www.sisram-medical.com |
| Share Registrar | 香港中央證券登記有限公司 |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Prospectus Date | 2017-09-05 |
| Offer Price | HK$ 8.88 / shares |
| Total Funds Raised | HK$ 293,040,000 |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
// First Day Performance
| First Day Close | Loading... |
| First Day Open | HK$ 8.79 |
| First Day Change | -8.56% |
| First Day Volume | 38948500.0 |
| First Day Turnover | 329538000.0 |
// Price Chart //
// Use of Proceeds
| Use of Proceeds | 1、約18.6%,或約128.4百萬港元,預期用于擴展我們的銷售渠道及分銷網絡以及加強我們的營銷力度;
2、約18.6%,或約128.4百萬港元,用于資本開支;
3、約14.0%,或約96.3百萬港元,預期用于研究及開發活動;
4、約9.3%,或約64.2百萬港元,預期將用于償還關聯方復星實業(香港)有限公司的收購貸款;
5、約29.5%,或約202.5百萬港元,預期將用于策略性收購、設立戰略合作關系,以及其他業務發展;
6、約10.0%,或約68.9百萬港元,預期用作營運資金及一般公司用途。 |
// Underwriting Syndicate //
联席保荐人 (2)
中国国际金融香港证券有限公司
富瑞金融集团香港有限公司
整体协调人 (3)
中国国际金融香港证券有限公司
富瑞金融集团香港有限公司
复星国际证券有限公司
联席账簿管理人 (5)
中国国际金融香港证券有限公司
富瑞金融集团香港有限公司
复星国际证券有限公司
海通国际证券有限公司
华泰金融控股(香港)有限公司
联席牵头经办人 (5)
中国国际金融香港证券有限公司
富瑞金融集团香港有限公司
复星国际证券有限公司
海通国际证券有限公司
华泰金融控股(香港)有限公司
// Cornerstone Investors //
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
| 1 |
纽顿医学美容集团有限公司 |
29,637,888 HKD |
— |
0.76% |
— |
6 months |
2018-03-19 |
| 2 |
上海自贸试验区一期股权投资基金合伙企业(有限合伙) |
116,999,328 HKD |
— |
2.99% |
— |
6 months |
2018-03-19 |
| 3 |
升泰有限公司 |
77,998,368 HKD |
— |
2.00% |
— |
6 months |
2018-03-19 |
// Directors & Management //
| Chairman | Lior Moshe DAYAN |
| Company Secretary | 方前厲 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 上海復星醫藥(集團)股份有限公司(71.16%) |
Disclaimer & Risk Warning
Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.
Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.
Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.
Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.
Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.